Rakuten Medical, a biotech subsidiary of Rakuten Group, is developing a novel photoimmunotherapy treatment for cancer that uses light to selectively destroy cancer cells. The company's technology, which combines a drug called Akalux with a light-administration platform called Alluminox, is currently in Phase 3 clinical trials in the U.S. with a target FDA submission in 2028. Rakuten Medical aims to expand its treatment beyond head and neck cancers to all solid tumors, requiring significant investment for research and development. AI
IMPACT Potential to shift cancer treatment paradigms from invasive surgery to light-activated therapies.
RANK_REASON Company is pursuing FDA approval for a novel cancer treatment, indicating a significant step in medical technology development. [lever_c_demoted from significant: ic=1 ai=0.7]
- Akalux
- Alluminox
- Hisataka Kobayashi
- Japan
- Minami Maeda
- Rakuten Group, Inc.
- Rakuten Medical
- San Diego
- United States Food and Drug Administration
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
